Eight companies. No two counting the same thing.
Every one of these is called a pipeline. Gland counts 389 US filings. Sai Life counts 150–160 molecules. Anthem counts 100+ projects. Laurus counts 96 dossiers. Divi’s counts 4 master files. Piramal updates once a year. Syngene gives no number at all.
“We should keep them as projects just given the amount of failures that happen at that stage.” Siva Chittor, CFO · Sai Life Sciences · 7 August 2026
And the count is not the business. Sai Life and Anthem are the same size — ₹2,192 crore against ₹2,124 crore. Sai Life has 33 molecules in commercial supply; Anthem has 14. Anthem earns 39.3%, Sai Life 28.8%.
Neuland sharpens it: its commercial count has been 19, 18, 19, 19 across four years, while the revenue those molecules produce rose three and a half times in one.
A sector, read end to end, and the companies as they are published. Roughly monthly. Nothing else, and one click to stop.
Not advice. Quotes are from the companies’ own earnings calls; figures from their filings.